The purpose of this study is to determine if CP-945,598 is effective in the treatment of obesity in type 2 diabetic patients.
The CP-945,598 program was terminated on November 3, 2008 due to changing regulatory perspectives on the risk/benefit profile of the CB1 class and likely new regulatory requirements for approval. No safety issues were involved in the termination decision.
Subjects receive placebo plus non-pharmacological weight loss program.
Subjects receive CP-945,598 plus non-pharmacological weight loss program.
Subjects receive CP-945,598 plus non-pharmacological weight loss program.
Buenos Aires, Argentina
Buenos Aires, Argentina
Buenos Aires, Argentina